Psyber focuses on the development of brain-computer interface-enabled (BCI) digital therapeutics for treating mental health issues. On April 7th, 2021, ATAI Life Sciences acquired a majority stake in Psyber. The terms of the transaction were not disclosed.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

EEG-based BCI devices record electrical activity in the brain for real-time interpretation of emotional, behavioural, and mental states. Rationale: We believe in giving patients more power during their therapeutic journey, while both improving and enhancing their therapeutic experience. How it works: Psyber empowers patients who are prescribed medication to achieve better mental health outcomes by offering personalized digitally enhanced, behaviour-changing experiences that complement their medication assisted therapy. Objective: Better outcomes, a better experience and better personalized behaviour change training than existing medication or behavioral therapy solutions currently offer.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.